Renal and Neurological Response with Eculizumab in a Patient with Transplant Associated Thrombotic Microangiopathy after Allogeneic Hematopoietic Progenitor Cell Transplantation

Sevindik O. G., ALACACIOĞLU İ., Katgi A., Solmaz S. M., Acar C., Piskin O., ...Daha Fazla

CASE REPORTS IN HEMATOLOGY, cilt.2015, 2015 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 2015
  • Basım Tarihi: 2015
  • Doi Numarası: 10.1155/2015/425410
  • Dergi Adı: CASE REPORTS IN HEMATOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Transplantation-associated thrombotic microangiopathy (TA-TMA) is a challenge after allogeneic hematopoietic progenitor cell transplantation, considering the diagnostic uncertainties and lack of established treatment. We report a 43-year-old male patient who was diagnosed as TA-TMA after allogeneic progenitor cell transplantation for a progressive ALK negative anaplastic large cell lymphoma and responded to eculizumab with dramatically improving neurological status and renal function. Rapid neurological and renal recovery achieved after eculizumab could support a possible relationship between complement activation and TA-TMA. Eculizumab should be a reasonable treatment approach in patients with TA-TMA after allogeneic hematopoietic progenitor cell transplantation.